Conditions: Cushing Disease
Keywords: Cushing's disease ACTH Cortisol ACTH dependent Cushing's disease
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and efficacy of pasireotide in participants with Cushing's disease.

Detailed description:

Arms:
arm 1: Participants received pasireotide 600 micrograms (μg) twice daily (BID) subcutaneously (SC) to achieve or maintain urinary free cortisol (UFC) normalization. If UFC levels were increased at any time, participants received 900 μg BID SC, until no safety or tolerability concerns were observed as per investigators assessment. If the participant was unable to tolerate the 900 μg BID, dosing of 600 μg three times a day was given.

Interventions: intervention 1: Pasireotide
Intervention descriptions: intervention 1: Pasireotide 600 μg or 900 μg was administered as an SC injection.

Protocol document: